About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« AstraZeneca's Cambridge Move | Main | Encoded Libraries Versus a Protein-Protein Interaction »

April 9, 2014

The State of Alzheimer's Research, 2014

Email This Entry

Posted by Derek

Via Bernard Munos on Twitter, here's a report from the New York Academy of Sciences looking at the current state of Alzheimer's research. Those various tabs are all live; you can get summaries of each one by clicking.

Looking them over breeds a mixture of hope and despair. The whole thing is themed around the 2025 target that many in the Alzheimer's world have been talking about. And while I understand the need for goals, etc., that year seems way too close. If a promising new compound were to be discovered this afternoon, it wouldn't make it. That brings up another point - many of the speakers at this meeting were talking about moving away from a "compound-centric" point of view. I can see (some of) the point, because there may well be other things to do for Alzheimer's patients. But it's also worth remembering that the reason people are talking like this is that no compounds have worked. This outlook is a second choice driven by necessity, not by some sort of obvious first principle.

And I think that, in the end, Alzheimer's will be arrested by compounds - more than one, most likely, and some of them are quite possibly going to be biomolecules, but compounds all the same. Reading the recommendations about adaptive clinical trials (good idea), broader cooperation and use of common clinical standards (another good idea), and all the others just make me wonder: clinical trials of what? That's the real stumper in this field; where to go next. How to go there is a topic that it's easier to reach agreement on.

Comments (42) + TrackBacks (0) | Category: Alzheimer's Disease


1. Anonymous on April 9, 2014 11:28 AM writes...

DL - What are your thoughts on the current state of the amyloid theory ? Jury still out? Is beta/gamma secretase inhibitor development tail chaising?

Permalink to Comment

2. Cato the Elder on April 9, 2014 12:51 PM writes...

"the worldwide costs of AD and related disorders (ADRD) were estimated at $604 billion, or 1% of GDP".

what? this number seems waaay to high. I'm curious what all they have lumped in with Alzheimer's to reach this number.

Permalink to Comment

3. Cato the Elder on April 9, 2014 12:52 PM writes...


Permalink to Comment

4. Imaging guy on April 9, 2014 1:14 PM writes...

#Cato the Elder
These numbers are highly conjectural. If you sum the economic costs attributed to different diseases, the total would be 20 to 30 times higher than the combined GDP of the world. They are generally used in constructing a sentence for the introductory section of the manuscripts.

Permalink to Comment

5. exGlaxoid on April 9, 2014 1:48 PM writes...

Wait until you have a parent or loved one with it. The minimum cost of the simplest care for someone with early Alzheimer's is about $2000 / month, once they get less able to care for themselves, it can rise to $4000-6000 per month. I have known quite a few people that needed that level of care for 2-5 years. That adds up fast and uses up people's savings quickly, and medicaid spending is going up rapidly due to it as well. It could easily cost that much worldwide, although much of that cost is likely in the US.

Permalink to Comment

6. Chemjobber on April 9, 2014 2:21 PM writes...

@4: So true.

Permalink to Comment

7. Anonymous on April 9, 2014 3:43 PM writes...

Indeed, lost productivity of full time care workers is by far the biggest cost. Consequently AD can easily cost USD 200,000 per patient per year, often for 5 to 10 years per patient. I'd rather die from cancer (or euthanasia) than inflict this kind of burden on my family and society when I go...

Permalink to Comment

8. Lane Simonian on April 9, 2014 3:52 PM writes...

I am going to repeat my favorite quote about peroxynitrites and Alzheimer's disease and then present the results of clinical trials using peroxynitrite scavengers to treat Alzheimer's disease.

[Clinical trials with over-the-counter supplements have concentrated either on items which suppress inflammation, or on antioxidants which scavenge oxygen derived free radicals. Most of these items have proved to be worthless in the treatment of Alzheimer's disease. Similarly most drugs used to treat Alzheimer's disease do little to slow the deterioration, but instead offer a mild temporary
symptom relief. However, evidence has been accumulating that the primary driver
of Alzheimer's disease is a nitrogen derived free radical called peroxynitrite,which may mediate both amyloid and tau accumulation as well as their toxicity. Excellent results have been obtained with peroxynitrite scavengers, with reversals of Alzheimer's disease in human clinical trials being repeatedly demonstrated. IMHO, the only thing which may be preventing the abolition of
Alzheimer's disease is the mental inertia of scientists, as well as the bureaucrats who fund them. Unfortunately, most bureaucrats keep throwing money into repeatedly testing discredited interventions, while ignoring successful ones. Common sense is anything but...]

Ferulic acid, syringic acid, vanillic acid, maltol, and p-coumaric acid in Panax ginseng (most highly concentrated in heat-processed ginseng).

A 24-week randomized open-label study with Korean red ginseng (KRG) showed cognitive benefits in patients with Alzheimer’s disease. To further determine long-term effect of KRG, the subjects were recruited to be followed up to 2 yr. Cognitive function was evaluated every 12 wk using the Alzheimer’s Disease Assessment Scale (ADAS) and the Korean version of the Mini Mental Status Examination (K-MMSE) with the maintaining dose of 4.5 g or 9.0 g KRG per d. At 24 wk, there had been a significant improvement in KRG-treated groups. In the long-term evaluation of the efficacy of KRG after 24 wk, the improved MMSE score remained without significant decline at the 48th and 96th wk. ADAS-cog showed similar findings. Maximum improvement was found around week 24. In conclusion, the effect of KRG on cognitive functions was sustained for 2 yr follow-up, indicating feasible efficacies of long-term follow-up for Alzheimer’s disease.

Nutr Neurosci. 2012 Jul 9. [Epub ahead of print]
Heat-processed ginseng enhances the cognitive function in patients with moderately severe Alzheimer's disease.
Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, Kim M.
Ginseng has been reported to improve cognitive function in animals and in healthy and cognitively impaired individuals. In this study, we investigated the efficacy of a heat-processed form of ginseng that contains more potent ginsenosides than raw ginseng in the treatment of cognitive impairment in patients with moderately severe Alzheimer's disease (AD).

Forty patients with AD were randomized into one of three different dose groups or the control group as follows: 1.5 g/day (n = 10), 3 g/day (n = 10), and 4.5 g/day (n = 10) groups, or control (n = 10). The Alzheimer's Disease Assessment Scale (ADAS) and Mini-Mental State Examination (MMSE) were used to assess cognitive function for 24 weeks.
The treatment groups showed significant improvement on the MMSE and ADAS. Patients with higher dose group (4.5 g/day) showed improvements in ADAS cognitive, ADAS non-cognitive, and MMSE score as early as at 12 weeks, which sustained for 24-week follow-up.

These results demonstrate the potential efficacy of a heat-processed form of ginseng on cognitive function and behavioral symptoms in patients with moderately severe AD.

Eugenol in rosemary and lemon balm essential oil and geraniol in lemon essential oil for cognition, and linalool in orange, lavender, and lemon balm essential oil (for behavior)

Objective:  Recently, the importance of non-pharmacological therapies for dementia has come to the fore. In the present study, we examined the curative effects of aromatherpay in dementia in 28 elderly people, 17 of whom had Alzheimer's disease (AD).

Methods:  After a control period of 28 days, aromatherapy was performed over the following 28 days, with a wash out period of another 28 days. Aromatherapy consisted of the use of rosemary and lemon essential oils in the morning, and lavender and orange in the evening. To determine the effects of aromatherpay, patients were evaluated using the Japanese version of the Gottfries, Brane, Steen scale (GBSS-J), Functional Assessment Staging of Alzheimer's disease (FAST), a revised version of Hasegawa's Dementia Scale (HDS-R), and the Touch Panel-type Dementia Assessment Scale (TDAS) four times: before the control period, after the control period, after aromatherpay, and after the washout period.

Results:  All patients showed significant improvement in personal orientation related to cognitive function on both the GBSS-J and TDAS after therapy. In particular, patients with AD showed significant improvement in total TDAS scores. Result of routine laboratory tests showed no significant changes, suggesting that there were no side-effects associated with the use of aromatherapy. Results from Zarit's score showed no significant changes, suggesting that caregivers had no effect on the improved patient scores seen in the other tests.

Conclusions:  In conclusion, we found aromatherapy an efficacious non-pharmacological therapy for dementia. Aromatherapy may have some potential for improving cognitive function, especially in AD patients.

Objective: To assess the efficacy and safety of Melissa officinalis extract using a fixed dose (60 drops/day) in patients with mild to moderate Alzheimer's disease.

Design: A four month, parallel group, placebo controlled trial undertaken in three centres in Tehran, Iran.

Methods: Patients with mild to moderate Alzheimer's disease aged between 65 and 80 years (n = 42; 18 women, 24 men) with a score of ≥ 12 on the cognitive subscale of Alzheimer's disease assessment scale (ADAS-cog) and ≤ 2 on the clinical dementia rating (CDR) were randomised to placebo or fixed dose of Melissa officinalis extract. The main efficacy measures were the change in the ADAS-cog and CDR-SB scores compared with baseline. Side effects were systematically recorded.

Results: At four months, Melissa officinalis extract produced a significantly better outcome on cognitive function than placebo (ADAS-cog: df = 1, F = 6.93, p = 0.01; CDR: df = 1, F = 16.87, p

Conclusions: Melissa officinalis extract is of value in the management of mild to moderate Alzheimer's disease and has a positive effect on agitation in such patients.

These are among the only clinical trials in which cognitive decline in Alzheimer's patients have been partially reversed and in which that reversal has been sustained. We can spend several more decades working on amyloid or tau or we can begin attacking what causes the disease.

Permalink to Comment

9. emjeff on April 9, 2014 5:39 PM writes...

Your statement about a compound discovered today not making the 2025 goal is an indictment of the current state of drug development. It's too damn complicated and takes far too long.

Permalink to Comment

10. Mike C on April 9, 2014 6:33 PM writes...

@ #9: An 11 year development period is optimistic even in an ideal environment when you consider the drug may have to be administered several years in advance of symptoms for it to show efficacy. 10 year trials anyone?

Permalink to Comment

11. Anonymous on April 10, 2014 2:42 AM writes...

Why do we continue to research target specific small molecules for systems biology problems like AD? We need molecules that target critical signaling or metabolic bottlenecks. Inhibiting something like oglcnacase (thiamet G) is going to be much more powerful than any molecule that only targets one pathway/cascade/protein. AD has been labeled as type 3 diabetes, and I'd bet everything from amyloid plaques, taus, etc etc are all secondary to one of the real primary drivers of AD- altered state of metabolism - that is a near universal feature of AD. DNA meh. Proteome meh. The next 100 years of biology are going to be focused on post translational modifications which take such a small genome and small proteome to generate the millions and millions of distinct molecular species that truly define the complexity of life. Ptm patterns, virtually all of them, are very reflective of cellular metabolic state. In a disease like AD, which is almost always accompanied by impaired glucose metabolism, you can therefore expect systems wide changes to occur in ptms which will profoundly alter pretty much every protein and genetic event in a cell with AD. Targeting specific proteins, receptors, or cascades isn't going to work. You need a systems solution which is going to involve some aspect of metabolism. A lead like thiamet G has begun to address this.

Permalink to Comment

12. sepisp on April 10, 2014 3:27 AM writes...

Why Alzheimer isn't cured is a mystery to me. I can understand the victim blaming that went on for decades with Helicobacter pylori-induced ulcers, since the symptom was nonspecific and clinicians had no idea the cause could even come from that direction. But, in this case, we have patients that display obvious symptoms, and there is also a distinctive microscopic finding identifying the disease. When the cause is identified, I think the change will be as dramatic as with tuberculosis vs. antibiotics or even with smallpox vs. vaccine. The cause is what is missing, not new drugs, yet.

That said, very few mental disorders or diseases of the brain have actual cures, drugs being only for management of symptoms; for instance, schizophrenia.

Permalink to Comment

13. Morten G on April 10, 2014 4:15 AM writes...

@13 Off-topic but mental diseases aren't all chronic.

So what are the alternatives to small-molecule therapy?
Inducing autophagy?
The dietary interventions that improve glucose sensitivity?

Permalink to Comment

14. simpl on April 10, 2014 4:28 AM writes...

Quick non-compound solutions (i.e. before 2025)
#12 caffein as a matabolism booster is already available
For Derek's more ambitious program, heat seaweed in a wok with fish oil (not to excess, it doesn't taste too good), then quench with cola to phosphorylate the lipids. Now, who has a seaweed library, and is anybody hungry? More seriously, isn't this why epidemologists have been looking at the Mediterranean diet?

Permalink to Comment

15. UK Chemist on April 10, 2014 6:41 AM writes...

So how do propose to speed it up exactly.

Permalink to Comment

16. Anonymous BMS Researcher on April 10, 2014 6:53 AM writes...

Imaging guy says "total..higher than the combined GDP of the world. They are generally used in constructing a sentence for the introductory section of the manuscripts..."

And we all quote each others' Intro sections!

I am reminded of the calculation some news reporter made during the 1973 Yom Kippur War -- he added up Arab claims for the numbers of Israeli aircraft shot down, pointing out that (1) the total vastly exceeded the number of planes Israel had when the war started and (2) Israeli planes were still flying.

Permalink to Comment

17. Lyle Langley on April 10, 2014 7:09 AM writes...

@12, sepisp...
"That said, very few mental disorders or diseases of the brain have actual cures, drugs being only for management of symptoms; for instance, schizophrenia."

I think you could make the argument that even management of symptoms in diseases such as SZ is not done well.

Permalink to Comment

18. exGlaxoid on April 10, 2014 9:19 AM writes...

#9, #11, #12, etc, Would all of the people complaining that drug development is too slow please give their solution and please cure all known illnesses within the next 2 years? Given the FDA's unwillingness to take any risks, the army of lawyers that sue everyone who sells any new drug or medical device, and the greed of everyone throughout the process, I don't know how any drugs make it through the process now.

If we found a solution to AZ in the next 10 years I would be astounded, but that does not mean we should not keep trying, as it will eventually be figured out, but it may take trying many ideas before it does. I would like it to be figured out soon, as AZ runs in the family, and I am not getting younger each year.

As for metabolism, Avandia was going into AZ trials when the overzealous people completely screwed that up, and it looked as good as anything else I have seen. Yes it had side effects, like every other drugs, but they were not worse than most any other drug, and it showed real potential.

The sad part is that a Pihkal type approach where many scientists test their own ideas on themselves might be faster than the current process of doing trials, which is going to take 5-10 years per compound, and only a few are tested per year, mostly on young, healthy people, which is not very helpful.

Permalink to Comment

19. Harrison on April 10, 2014 10:10 AM writes...

@12, The AD field spent years chasing AB plaques. In the end those drugs might be the equivalent of a drug that removes chicken pox scabs.

@18, Unless you have some inside information, Rosiglitazone failed it's Phase II trial. The original signal was observed in a sub-population based on apoE genotype and which was not subsequently replicated. Don't worry, though, because Pioglitazone is going into an MCI trial run by the same people despite it's less-than-stellar brain penetration. Another metabolic target, HSD-1 also failed in a Phase II AD study, and the jury is still out on Inhalable Insulin.

Permalink to Comment

20. Lane Simonian on April 10, 2014 11:10 AM writes...

#14 Mediterranean diet, epidemiology, and Alzheimer's disease.

Neurology. 2007 Sep 11;69(11):1084-93.
Mediterranean diet and Alzheimer disease mortality.
Scarmeas N1, Luchsinger JA, Mayeux R, Stern Y.

We previously reported that the Mediterranean diet (MeDi) is related to lower risk for Alzheimer disease (AD). Whether MeDi is associated with subsequent AD course and outcomes has not been investigated.

To examine the association between MeDi and mortality in patients with AD.

A total of 192 community-based individuals in New York who were diagnosed with AD were prospectively followed every 1.5 years. Adherence to the MeDi (0- to 9-point scale with higher scores indicating higher adherence) was the main predictor of mortality in Cox models that were adjusted for period of recruitment, age, gender, ethnicity, education, APOE genotype, caloric intake, smoking, and body mass index.

Eighty-five patients with AD (44%) died during the course of 4.4 (+/-3.6, 0.2 to 13.6) years of follow-up. In unadjusted models, higher adherence to MeDi was associated with lower mortality risk (for each additional MeDi point hazard ratio 0.79; 95% CI 0.69 to 0.91; p = 0.001). This result remained significant after controlling for all covariates (0.76; 0.65 to 0.89; p = 0.001). In adjusted models, as compared with AD patients at the lowest MeDi adherence tertile, those at the middle tertile had lower mortality risk (0.65; 0.38 to 1.09; 1.33 years' longer survival), whereas subjects at the highest tertile had an even lower risk (0.27; 0.10 to 0.69; 3.91 years' longer survival; p for trend = 0.003).

Adherence to the Mediterranean diet (MeDi) may affect not only risk for Alzheimer disease (AD) but also subsequent disease course: Higher adherence to the MeDi is associated with lower mortality in AD. The gradual reduction in mortality risk for higher MeDi adherence tertiles suggests a possible dose-response effect.

#11 Alzheimer's disease has been called but is not a type 3 diabetes. High levels of glucose (pre-dabetic or diabetic) lead to high levels of myo-inositol in the brain. High blood pressure due to high sodium levels and Down syndrome lead to high levels of myo-inositol in the brain. All are risk factors for Alzheimer's disease. Myo-inositol leads to peroxynitrites and amyloid. Elements/compounds such as lithium and scyllo-inositol limit myo-inositol formation. Ferulic acid binds to myo-inositol. The latter is the safest compound to limit the effects of myo-inositol.

Comparison of patients with progressive disease versus those who developed AD for the cingulate gyrus showed the increased myo-inositol-to-water ratio to be 72% predictive for dementia; similarly for the hippocampus, it was 70% predictive for dementia.

The researchers also suspect that high levels of myo-inositol could play a role in predisposing people with Down syndrome to early-onset Alzheimer's disease.

The molecule is known to promote the formation of amyloid plaques - a hallmark of Alzheimer's.

Reducing concentration

Lead researcher Professor Declan Murphy said: "We have shown in this study that adults with Down's syndrome have a significantly higher concentration of myo-inositol in the hippocampal region of their brains, and this increase is associated with a reduced cognitive ability.

"We are now carrying out more studies to see if we can reduce the concentration of myo-inositol in the brains of people with Down's.

"We hope that if we can do this, it will be a new way of treating this devastating disorder."

Alzheimer's disease is not insulin resistance in the brain (although peroxynitrites contribute to insulin resistance), it is likely the result of the disruption of glucose transport and metabolism caused by peroxynitrites (or its lipid peroxidation product HNE).

Impairment of Glucose and Glutamate Transport and Induction of Mitochondrial Oxidative Stress and Dysfunction in Synaptosomes by Amyloid β-Peptide: Role of the Lipid Peroxidation Product 4-Hydroxynonenal

#1, #12 Beta-secretase activation is likely caused by peroxynitrite and hydrogen peroxide oxidation of cysteine and occurs primarily within lipid rafts (which explains the recent study linking particular lipid markers with Alzheimer's disease).

Mol Neurodegener. 2011 Mar 3;6:17.
Differential regulation of BACE1 expression by oxidative and nitrosative signals.
Kwak YD1, Wang R, Li JJ, Zhang YW, Xu H, Liao FF.

These novel NO-mediated regulatory mechanisms likely protect BACE1 from being further oxidized by excessive oxidative stress, as from H2O2 and peroxynitrite which are known to upregulate BACE1 and activate the enzyme, resulting in excessive cleavage of APP and Aβ generation; they likely represent the crucial house-keeping mechanism for BACE1 expression/activation under physiological conditions.

Work upstream of beta-secretase and early on you have a chance to stop the progression of Alzheimer's disease. By contrast, inhibiting beta-secretase itself likely does no good. Hopefully, the drug companies trying to develop beta-secretase inhibitors are working upstream of BACE1.

Gamma secretase is controlled by intracellular calcium levels and makes little difference in the progression of Alzheimer's disease. It leads to amyloid oligomers and plaques and may increase levels of peroxynitrites but is not required for Alzheimer's disease. It is possible to have Alzheimer's disease only with the c-terminal fragment of the amyloid precursor protein which is caused in part by the peroxynitrite activation of BACE1.

J Neurochem. 2001 Jul;78(1):109-20.
C-terminal fragment of amyloid precursor protein induces astrocytosis.
Bach JH1, Chae HS, Rah JC, Lee MW, Park CH, Choi SH, Choi JK, Lee SH, Kim YS, Kim KY, Lee WB, Suh YH, Kim SS.
Author information
One of the pathophysiological features of Alzheimer's disease is astrocytosis around senile plaques. Reactive astrocytes may produce proinflammatory mediators, nitric oxide, and subsequent reactive oxygen intermediates such as peroxynitrites. In the present study, we investigated the possible role of the C-terminal fragment of amyloid precursor protein (CT-APP), which is another constituent of amyloid senile plaque and an abnormal product of APP metabolism, as an inducer of astrocytosis. We report that 100 nM recombinant C-terminal 105 amino acid fragment (CT105) of APP induced astrocytosis morphologically and immunologically. CT105 exposure resulted in activation of mitogen-activated protein kinase (MAPK) pathways as well as transcription factor NF-kappaB. Pretreatment with PD098059 and/or SB203580 decreased nitric oxide (NO) production and nuclear factor-kappa B (NF-kappaB) activation. But inhibitors of NF-kappaB activation did not affect MAPKs activation whereas they abolished NO production and attenuated astrocytosis. Furthermore, conditioned media derived from CT105-treated astrocytes enhanced neurotoxicity and pretreatment with NO and peroxynitrite scavengers attenuated its toxicity. These suggest that CT-APP may participate in Alzheimer's pathogenesis through MAPKs- and NF-kappaB-dependent astrocytosis and iNOS induction [order mixed up, but otherwise perfect anaylsis].

Efforts to treat Alzheimer's disease by reducing levels of amyloid plaques, oligomers (see recent PRANA Pbt2 study), or gamma secretases should be dead. Efforts to treat Alzheimer's disease by inhibiting beta secretase will likely not succeed unless they are working upstream of BACE1.

Plant compounds such as ferulic acid limit the damage done by myo-inositol, inhibit the production of peroxynitrites, scavenge peroxynitrites, and reverse part of their damage. They have been highly successful in reducing neuropsychiatric problems in people with Alzheimer's disease and other forms of dementia. Combine ferulic acid with more bioavailable peroxynitrite scavengers such as eugenol in various essential oils or vanillic acid and syringic acid in heat-processed ginseng and you can partially reverse cognitive decline in Alzheimer's disease. The studies showing this are small, but the results don't lie and they make perfect sense once the biochemistry behind Alzheimer's disease is understood.

Permalink to Comment

21. anon on April 10, 2014 12:14 PM writes...

One of the biggest hurdles I see in treating AD is detecting it early enough and being able to distinguish it readily from other types of dementia. While analogues such as florbeptir appear promising, their predictive potential for AD has yet to be determined and there are other issues that remain to be resolved. Even establishing florbetapir is going to take many more years and I am not terribly optimistic.
Secondly, intervening with a disease modifying drug is going to require long-term clinical trials. Given the state of funding for AD and/or pharma being willing to attempt such a trial given its cost, I really don't see anything happening.

Permalink to Comment

22. Anonymous on April 10, 2014 12:46 PM writes...


Myo-inositol is biosynthesis is a branch off of primary glycolytic metabolism. MIPS, which is highly regulated and likely impaired in diseases such as AD, cancer, or diabetes, transforms glucose-6-phosphate into 1D-myo-inositol-3-p. Also, many, many, if not all of the effectors that utilize inositol derived messengers are modified by O-GlcNAc, which is also a product of metabolic states. AD is almost always accomanied by lower rates of glucose metabolism. O-GlcNAc modification of almost all intracellular proteins is going to be perturbed. On top of that, many of the precursors used for protein glycosylation, which is absolutely critical for correct protein folding, are derived also from pathways that branch from glycolysis. Is it surprising then that unfolded proteins are a problem in a disease like AD, when you have depressed glucose/glycolytic metabolism. Glucose receptors themselves are glycosylates--glycans can affect their transport, half life, and even total amount of GLUT transporters on the surface. Primary glucose metabolism cross talks with an insane amount of signaling cascades, DNA events, and protein functions.

Part of the problem as well is the fact that many of the scientists that are at companies and in positions of power are not trained or don't even know about the most up to date cell biology. Systems problems need systems approaches, such as attacking altered metabolic states.

Permalink to Comment

23. Harrison on April 10, 2014 2:24 PM writes...

@20: Scyllo-inositol failed to improve core AD symptoms in a 78-week Phase 2 study:

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease.
Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM; ELND005-AD201 Investigators. Neurology. 2011 Sep 27;77(13):1253-62. doi: 10.1212/WNL.0b013e3182309fa5. Epub 2011 Sep 14. PMID:21917766[PubMed - indexed for MEDLINE]

However, in a subsequent post-hoc analysis it did appear to decrease agitation and aggression (AAIC, 2013).

Permalink to Comment

24. Lane Simonian on April 10, 2014 2:41 PM writes...

# 22 Oxidation and nitration may be one of several factors affecting glucose metabolism and transport. Other factors may indeed also be involved in Alzheimer's disease.

High glucose levels in the brain is one of the factors that likely leads to increased myo-inositol levels in the brain during Mild Cognitive Impairment and early Alzheimer's disease. The oxidation and nitration of tyrosine receptor kinases and g protein-coupled receptors later often limits the production of inositol 1,4,5 triphosphate via phospholipase C beta and gamma and the recycling of myo-inositol. However, several factors can independently activate g proteins and thus phospholipase C beta including aluminium fluoride, sodium fluoride, and perhaps stress. In people with Alzheimer's disease who continue to have high levels of myo-inositol, various neuropsychiatric problems are present.

Elan’s Gene Kinney recounted how falling myoinositol levels were discovered when company researchers used NMR to confirm scyllo-inositol had made its way into the brain. The researchers noticed that, as brain scyllo-inositol rose, its myo-isoform fell. Going back to animal models, they found that the myo isoform dropped by as much as 70 percent when the animals imbibed drinking water laced with scyllo-inositol. Why is this important? Previously, researchers had reported elevated brain myoinositol in patients with AD, Down's syndrome, and bipolar disorder, said Kinney (see Miller et al., 1993). More recently, a group in Japan correlated elevated brain myoinositol with behavioral and psychological problems in AD patients. Lithium, which has been used for many years to treat neuropsychiatric disorders, may work in part by reducing myoinositol. In fact, a 30 percent reduction of myoinositol is predictive of lithium efficacy, said Kinney. By reducing myoinositol, could scyllo-inositol treat neuropsychiatric symptoms in AD patients?

Given the poor safety profile of these compounds, ferulic acid may be a beneficial alternative.

Preparation of a (+/-)-1,6-di-O-feruloyl-myo-inositol derivative: an efficient method for introduction of ferulic acid to 1,6-vicinal hydroxyl groups of myo-inositol.

Geriatr Gerontol Int. 2011 Jul;11(3):309-14. doi: 10.1111/j.1447-0594.2010.00687.x. Epub 2011 Jan 28.
Effect of ferulic acid and Angelica archangelica extract on behavioral and psychological symptoms of dementia in frontotemporal lobar degeneration and dementia with Lewy bodies.
Kimura T1, Hayashida H, Murata M, Takamatsu J.

The behavioral and psychological symptoms of dementia place a heavy burden on caregivers. Antipsychotic drugs, though used to reduce the symptoms, frequently decrease patients' activities of daily living and reduce their quality of life. Recently, it was suggested that ferulic acid is an effective treatment for behavioral and psychological symptoms. We have also reported several patients with dementia with Lewy bodies showing good responses to ferulic acid and Angelica archangelica extract (Feru-guard). The present study investigated the efficacy of Feru-guard in the treatment of behavioral and psychological symptoms in frontotemporal lobar degeneration and dementia with Lewy bodies.

We designed a prospective, open-label trial of daily Feru-guard (3.0 g/day) lasting 4 weeks in 20 patients with frontotemporal lobar degeneration or dementia with Lewy bodies. Behavioral and psychological symptoms of dementia were assessed at baseline and 4 weeks after the start of treatment, using the Neuropsychiatric Inventory. The Neuropsychiatric Inventory scores were analyzed using the Wilcoxon rank sum test.

Treatment with Feru-guard led to decreased scores on the Neuropsychiatric Inventory in 19 of 20 patients and significantly decreased the score overall. The treatment also led to significantly reduced subscale scores on the Neuropsychiatric Inventory ("delusions", "hallucinations", "agitation/aggression", "anxiety", "apathy/indifference", "irritability/lability" and "aberrant behavior"). There were no adverse effects or significant changes in physical findings or laboratory data.

Feru-guard may be effective and valuable for treating the behavioral and psychological symptoms of dementia in frontotemporal lobar degeneration and dementia with Lewy bodies.

Effects of ferulic acid and Angelica archangelica extract (Feruguard) in patients with Alzheimer's disease
Kiyoshi Kanaya

Background: Feruguard is a health food supplement composed of ferulic acid extracted from rice bran and garden angelica obtained from Angelica archangelica. In recent years, Feruguard has been reported to be effectiv